Paul Tudor Jones's NEO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 156,642 shares of NeoGenomics, Inc. (NEO) worth $1.84 M, representing 0.00% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in NEO, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 580,491 shares. Largest reduction occurred in Q3 2025, reducing 320,361 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's NeoGenomics (NEO) Holding Value Over Time
Track share changes against reported price movement
Quarterly NeoGenomics (NEO) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -218,709 | Reduce 58.27% | 156,642 | $11.76 |
| Q3 2025 | -320,361 | Reduce 46.05% | 375,351 | $7.72 |
| Q2 2025 | +580,491 | Add 503.81% | 695,712 | $7.31 |
| Q1 2025 | +27,868 | Add 31.90% | 115,221 | $9.49 |
| Q4 2024 | -129,945 | Reduce 59.80% | 87,353 | $16.48 |
| Q3 2024 | +67,490 | Add 45.05% | 217,298 | $14.75 |
| Q2 2024 | +149,808 | New Buy | 149,808 | $13.87 |
| Q1 2024 | -28,844 | Sold Out | 0 | $0.00 |
| Q4 2023 | +28,844 | New Buy | 28,844 | $16.18 |
| Q3 2023 | -165,391 | Sold Out | 0 | $0.00 |
| Q2 2023 | +32,889 | Add 24.82% | 165,391 | $16.07 |
| Q1 2023 | +18,293 | Add 16.02% | 132,502 | $0.02 |
| Q4 2022 | +58,779 | Add 106.04% | 114,209 | $0.01 |
| Q3 2022 | +55,430 | New Buy | 55,430 | $8.61 |
| Q2 2022 | -24,768 | Sold Out | 0 | $0.00 |
| Q1 2022 | +24,768 | New Buy | 24,768 | $12.15 |
| Q2 2021 | -11,000 | Sold Out | 0 | $0.00 |
| Q1 2021 | +11,000 | New Buy | 11,000 | $48.27 |
| Q1 2019 | -77,896 | Sold Out | 0 | $0.00 |
| Q4 2018 | +32,884 | Add 73.06% | 77,896 | $12.61 |
| Q3 2018 | +3,470 | Add 8.35% | 45,012 | $15.35 |
| Q2 2018 | +25,162 | Add 153.61% | 41,542 | $13.12 |
| Q1 2018 | +16,380 | New Buy | 16,380 | $8.18 |
| Q2 2017 | -45,632 | Sold Out | 0 | $0.00 |
| Q1 2017 | +18,762 | Add 69.83% | 45,632 | $7.89 |
| Q4 2016 | +15,927 | Add 145.55% | 26,870 | $8.56 |
| Q3 2016 | -3,236 | Reduce 22.82% | 10,943 | $8.22 |
| Q2 2016 | +14,179 | New Buy | 14,179 | $8.04 |
Paul Tudor Jones's NeoGenomics Investment FAQs
Paul Tudor Jones first purchased NeoGenomics, Inc. (NEO) in Q2 2016, acquiring 14,179 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held NeoGenomics, Inc. (NEO) for 28 quarters since Q2 2016.
Paul Tudor Jones's largest addition to NeoGenomics, Inc. (NEO) was in Q2 2025, adding 695,712 shares worth $5.09 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 156,642 shares of NeoGenomics, Inc. (NEO), valued at approximately $1.84 M.
As of the Q4 2025 filing, NeoGenomics, Inc. (NEO) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in NeoGenomics, Inc. (NEO) was 695,712 shares, as reported at the end of Q2 2025.